NUVB - Nuvation Bio

-

$undefined

N/A

(N/A)

Nuvation Bio NEW YORK STOCK EXCHANGE INC.:NUVB Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco.

Location: | Website: www.nuvationbio.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

454.9M

Cash

549.1M

Avg Qtr Burn

-24.79M

Short % of Float

4.84%

Insider Ownership

26.86%

Institutional Own.

44.60%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Taletrectinib (ROS1 inhibitor) Details
Cancer, Non-small cell lung carcinoma

NDA

Submission

Safusidenib [mIDH1 inhibitor] Details
Cancer, High-grade Glioma

Phase 2

Data readout

NUV-1511 Details
Solid tumor/s

Phase 1/2

Data readout

NUV-868 +enzalutamide Details
Cancer, Solid tumor/s, Castration-resistant prostate cancer

Phase 1b

Data readout

NUV-868 +olaparib Details
Solid tumor/s, Cancer, Pancreatic cancer, Ovarian cancer, Castration-resistant prostate cancer, Triple-negative breast cancer

Phase 1b

Data readout

Phase 1

Data readout

NUV-422 (CDK inhibitor) Details
High-grade Glioma , Solid tumor/s, Cancer, Prostate cancer, Breast cancer, Castration-resistant prostate cancer, Metastatic breast cancer

Failed

Discontinued